Analyst Ritu Baral of TD Cowen maintained a Buy rating on Krystal Biotech (KRYS – Research Report), retaining the price target of $208.00.
Ritu Baral has given his Buy rating due to a combination of factors including Krystal Biotech’s stable financial performance and promising future prospects. The company’s reported Vyjuvek revenue for the fourth quarter of 2024 was $91.1 million, aligning well with prior estimates and consensus. This reflects a steady uptake that is expected to spur further growth in 2025 and beyond.
Krystal Biotech’s strategic pricing and reimbursement strategies have also played a significant role in Baral’s positive outlook. With Vyjuvek priced at $25.23K per vial, the company offers cost predictability for plans, maintaining a patient-level cap of $900K. Moreover, with substantial patient reimbursement approvals and an increasing diagnosis rate, Baral anticipates the company will meet its target of 720 patients on Vyjuvek by the end of 2025, reinforcing the Buy recommendation.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KRYS in relation to earlier this year.